Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Menlo Park, California Clinical Trials

A listing of Menlo Park, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (14) clinical trials

GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain

The treatment intervention to be tested in this clinical trial is Graded in-vivo Exposure Treatment (GET Living) compared to Typical Pain Management (TPM) in adolescents with chronic musculoskeletal pain. Participants will be randomized into GET Living or TPM, and will be instructed to not seek new treatments for pain for ...

Phase N/A

0.96 miles

Learn More »

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).

Phase

1.36 miles

Learn More »

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

The purpose of this study is to evaluate itacitinib in combination with corticosteroids for the treatment of Grades II to IV acute graft-versus-host disease (aGVHD) in steroid-naive pediatric participants.

Phase

1.36 miles

Learn More »

AVATAR Anesthesia Alternative in Pediatric Radiotherapy: A Multi-Center Study

To determine the success rate of the AVATAR audio-visual system. All patients enrolled in the study will be counted, and each patient who is able to undergo at least one fraction without anesthesia will count as a success while each patient who does not have at least one fraction without ...

Phase N/A

1.36 miles

Learn More »

Regional Anesthesia for Cardiothoracic Enhanced Recovery (RACER) Study

The erector spinae plane block is a novel regional anesthetic technique that allows for analgesia of the thorax and abdomen with a peripheral nerve block. The goals of this study are to determine if bilateral erector spinae plane blocks (ESPB) after sternotomy for congenital heart repair in high risk children ...

Phase N/A

1.36 miles

Learn More »

Hypotension Prediction Index Study (HPI Study)

A prospective, single-arm, open-label, multicenter post-approval study to determine whether the use of the Acumen HPI Software to guide intraoperative hemodynamic management in non-cardiac surgery reduces the duration of intraoperative hypotension below a threshold of Mean Arterial Pressure (MAP)

Phase N/A

1.88 miles

Learn More »

Chromogranin A as Blood Marker in Cancer Patients

A general characteristic for neuroendocrine tumors (NET) is expression of chromogranin A (CgA), which is released from neuroendocrine cells, occasionally together with cell specific hormones such as gastrin, insulin, somatostatin, and serotonin in functional tumors. Human CgA is an acidic 439 amino acid protein with a sequence containing several mono- ...

Phase N/A

2.3 miles

Learn More »

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Approximately 650 adult participants (18 to 70 years old, inclusive) with DM1 will be enrolled at 15 centers (up to 70 patients will be recruited at each site). No treatment will be administered as part of this study. Participants will receive standard of care as determined by the investigators. Study ...

Phase N/A

2.3 miles

Learn More »

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Primary Objective of the Master Protocol (LUNGMAP) The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol. Secondary Objectives Screening Success Rate Objective To evaluate the screen success rate defined as ...

Phase

2.48 miles

Learn More »

Exploratory Study to Investigate the Bioactivity Ocular and Systemic Safety Tolerability and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD DME and RVO

This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg

Phase

3.5 miles

Learn More »